Thursday, 5 November 2026 Every NSE & BSE earnings call, live and summarised
ALFA Concalls Every earnings call, live and summarised

Earnings calls

Poly Medicure concalls

Every Poly Medicure earnings call we streamed: the live audio and our summary of what management said.

Calls

Thu, 5 Nov

Poly Medicure

POLYMEDQ2 FY27 earnings call

Consolidated Q2 revenue rose 31%, but H1 organic growth was only 14%. Pendra Care is loss-making and Italy tenders are delayed. FY27 revenue guidance was reaffirmed and the standalone margin band raised.

Summary ready

Q2 FY27: key takeaways

Call page →

Consolidated Q2 revenue rose 31%, but H1 organic growth was only 14%. Pendra Care is loss-making and Italy tenders are delayed. FY27 revenue guidance was reaffirmed and the standalone margin band raised.

Outlook

FY27 consolidated revenue ₹2,300–2,400 Cr reaffirmed; standalone EBITDA margin band raised to 26–27.5%.

Earlier call summaries

All →
16:44 IST BSE
Earnings Call

Poly Medicure Earnings Call: Key Takeaways

Poly Medicure reported FY26 consolidated revenue of ₹1,875cr (up 12.3%) and standalone EBITDA of ₹446cr (26.8% margin). The company is transitioning from product-focused to therapy-focused segments like Cardiology and Renal.

Poly Medicure Ltd: key numbers

Share price
₹1,615.00
Market cap
₹16,370 Cr
Revenue (annual)
₹1,875 Cr
Net profit (annual)
₹322.1 Cr
P/E (TTM)
52.0×Sector 54.5×
Promoter holding
62.42%+0.00% QoQ
FII holding
5.36%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.